Wedbush Equities Analysts Reduce Earnings Estimates for CMPX

Key Points

• Wedbush analysts have reduced their Q4 2026 earnings per share (EPS) estimate for Compass Therapeutics from $0.01 to $0.00, while the consensus estimate for the current full-year earnings stands at ($0.36) per share.
• Compass Therapeutics has received mixed ratings from analysts, with targets ranging from $9.00 to $32.00 and a consensus target price of $12.67, indicating a generally bullish outlook.
• The company's shares have increased 23.7% recently, closing at $3.34, and it has a market capitalization of approximately $461.86 million.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Investment analysts at Wedbush cut their Q4 2026 earnings per share (EPS) estimates for Compass Therapeutics in a research note issued on Monday, August 11th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of $0.00 for the quarter, down from their prior forecast of $0.01. The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Compass Therapeutics' FY2027 earnings at $0.27 EPS, FY2028 earnings at $0.94 EPS and FY2029 earnings at $1.55 EPS.

CMPX has been the subject of several other reports. Guggenheim decreased their target price on Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, May 9th. D. Boral Capital reiterated a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a research report on Monday, April 28th. Raymond James Financial upgraded Compass Therapeutics to an "outperform" rating and set a $9.00 target price for the company in a research report on Tuesday, July 1st. Finally, HC Wainwright reiterated a "buy" rating and set a $24.00 target price on shares of Compass Therapeutics in a research report on Monday, April 21st. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $12.67.

Compass Therapeutics Stock Up 23.7%

Shares of CMPX opened at $3.34 on Tuesday. The company has a market cap of $461.86 million, a PE ratio of -8.15 and a beta of 1.49. The business has a fifty day moving average of $2.74 and a 200 day moving average of $2.49. Compass Therapeutics has a 52-week low of $1.12 and a 52-week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01).

Institutional Trading of Compass Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Vontobel Holding Ltd. bought a new stake in shares of Compass Therapeutics in the first quarter valued at about $57,000. Squarepoint Ops LLC bought a new stake in shares of Compass Therapeutics in the fourth quarter valued at about $35,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Compass Therapeutics by 31.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company's stock valued at $69,000 after acquiring an additional 11,326 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Compass Therapeutics by 25.2% in the fourth quarter. Renaissance Technologies LLC now owns 278,600 shares of the company's stock valued at $404,000 after acquiring an additional 56,000 shares in the last quarter. Finally, ProShare Advisors LLC raised its holdings in shares of Compass Therapeutics by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock valued at $42,000 after acquiring an additional 9,451 shares in the last quarter. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.